Cohance Lifesciences Ltd. NSE: COHANCE | BSE: 543064

Cohance Lifesciences Ltd. Live Share Price Today, Share Analysis and Chart

Name: Cohance Lifesciences Ltd.: Is Infosys Ltd. worth buying?
Item: Cohance Lifesciences Ltd.
Rating: 1.922708375
Author: Trendlyne DVM scores

Expensive Underperformer

about

Incorporated in 2018, Suven Pharmaceuticals is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Specialty Chemicals and formulated drugs under contract...

869.30 -30.60 (-3.40%)

Near 52W Low of ₹856.30

620.0K

NSE+BSE Volume

NSE 26 Sep, 2025 3:31 PM (IST)

Loading... You have run out of DVM views! Check usage

Subscribe now to see details

Medium Financial Strength

50.0 / 100

Expensive Valuation

21.7 / 100

Technically Bearish

32.2 / 100

Expensive Underperformer These stocks are medium in financial scores. They have bad valuation and technical scores as well. View Similar Embed DVM

1,224

1Yr Price target upside is 41%

8 analysts

Cohance Lifesciences Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

VOTE: Is Suven Pharmaceuticals Ltd. worth buying?

28 Votes:

Buy 64.29%

Sell 17.86%

Hold 17.86%

Cohance Lifesciences Ltd. Live Share Price Today, Share Analysis and Chart

Incorporated in 2018, Suven Pharmaceuticals is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Specialty Chemicals and formulated drugs under contract...

Near 52W Low of ₹856.30

SWOT Analysis

Cohance Lifesciences Live Price Chart